Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 16, 2025Journal of Antimicrobial ChemotherapyOpen Access

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKirby Patterson-FahyRCRobyn CarterSBScott C. Bell

Discussion

Loading...

Member takes

Overview

In vitro analysis reveals sulbactam/durlobactam improves susceptibility to cefuroxime and β-lactam antibiotics for Mycobacterium abscessus, indicating potential clinical efficacy.

Key Points

  • Sulbactam/durlobactam significantly improves the susceptibility of Mycobacterium abscessus to cefuroxime and other β-lactam antibiotics, enhancing treatment options.
  • The study shows a notable decrease in the minimum inhibitory concentrations (MICs) with combinations of sulbactam/durlobactam and meropenem or cefuroxime.
  • Antibiotic susceptibility testing was conducted according to Clinical Laboratory Standards Institute (CLSI) standards on clinical isolates of Mycobacterium abscessus.
  • The findings may enable improved strategies for treating Mycobacterium abscessus infections, although in vivo validation is needed.

Cite This Study

Patterson-Fahy et al. (2025) studied this question.

synapsesocial.com/papers/6940acc83507a57a7f7a44dahttps://doi.org/10.1093/jac/dkaf441
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for Mycobacterium abscessus Lung Disease2025
  2. 2The Role of β-Lactam Antibiotics in Treating <i>Mycobacterium abscessus</i>: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials2025
  3. 3From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem?2025
  4. 4P40 Evaluation of sulbactam/durlobactam activity against carbapenem-resistant <i>Acinetobacter baumannii</i> in India: an institutional experience2025
  5. 5The promise and pitfalls: interpreting dual β-lactam success in <i>Mycobacterium abscessus</i> with caution2025